Does Immunohistochemistry Provide Additional Prognostic Data in Gastrointestinal Stromal Tumors?

被引:12
|
作者
Demir, Lutfiye [1 ]
Ekinci, Nese [2 ]
Erten, Cigdem [1 ]
Kucukzeybek, Yuksel [1 ]
Alacacioglu, Ahmet [1 ]
Somali, Isil [3 ]
Can, Alper [1 ]
Dirican, Ahmet [1 ]
Bayoglu, Vedat [1 ]
Akyol, Murat [1 ]
Cakalagaoglu, Fulya [2 ]
Tarhan, Mustafa Oktay [1 ]
机构
[1] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Med Oncol, Izmir, Turkey
[2] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Pathol, Izmir, Turkey
[3] Dokuz Eylul Univ, Inst Oncol, Dept Med Oncol, TR-35210 Alsancak, Turkey
关键词
Gastrointestinal stromal tumor; immunohistochemistry; predictive potential; prognosis; IMATINIB MESYLATE; C-KIT; GIST; MUTATIONS; SURVIVAL; RECURRENCE; RESISTANCE; DIAGNOSIS;
D O I
10.7314/APJCP.2013.14.8.4751
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To investigate the predictive and prognostic effects of clinicopathologic and immunohistochemical (IHC) features in patients with gastrointestinal stromal tumours (GISTs). Materials and Methods: Fifty-six patients who were diagnosed with GIST between 2002 and 2012 were retrospectively evaluated. Relationships between clinicopathologic/immunohistochemical factors and prognosis were investigated. Results: Median overall survival (OS) of the whole study group was 74.9 months (42.8-107.1 months), while it was 95.2 months in resectable and 44.7 months in metastatic patients respectively (p=0.007). Epitheliolid tumor morphology was significantly associated with shortened OS as compared to other histologies (p=0.001). SMA(+) tumours were significantly correlated with low (<10/50HPF) mitotic activity (p=0.034). Moreover, SMA(+) patients tended to survive longer and had significantly longer disease-free survival (DFS) times than SMA (-) patients (37.7 months vs 15.9 months; p=0.002). High Ki-67 level (>= 30%) was significantly associated with shorter OS (34 vs 95.2 months; 95% CI; p=0.001). CD34 (-) tumours were significantly associated with low proliferative tumours (Ki-67<% 10) (p=0.026). Median PFS (progression-free survival) of the patients who received imatinib was 36 months (27.7-44.2 months). CD34 (-) patients had significantly longer PFS times than that of negative tumours; (50.8 vs 29.8 months; p=0.045). S100 and desmin expression did not play any role in predicting the prognosis of GISTs. Multivariate analysis demonstrated that >= 10/50HPF mitotic activity/HPF was the only independent factor for risk of death in GIST patients. Conclusions: Despite the negative prognostic and predictive effect of high Ki-67 and CD34 expression, mitotic activity remains the strongest prognostic factor in GIST patients. SMA positivity seems to affect GIST prognosis positively. However, large-scale, multicenter studies are required to provide supportive data for these findings.
引用
收藏
页码:4751 / 4758
页数:8
相关论文
共 50 条
  • [41] Gastrointestinal Stromal Tumors Risk Assessment and Adjuvant Therapy
    Joensuu, Heikki
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (05) : 889 - 904
  • [42] Gastrointestinal stromal tumors: a focus on the impact of interstitial cells of Cajal in disease development
    Radu, Petru
    Zurzu, Mihai
    Tigora, Anca
    Paic, Vlad
    Bratucu, Mircea
    Garofil, Dragos
    Surlin, Valeriu
    Patrascu, Stefan
    Prunoiu, Virgiliu
    Coman, Ionut Simion
    Georgescu, Valentin
    Chivu, Razvan Daniel
    Popa, Florian
    Strambu, Victor
    Ioan, Raluca Gabriela
    JOURNAL OF MIND AND MEDICAL SCIENCES, 2024, 11 (02): : 412 - 419
  • [43] Prognostic criteria in patients with gastrointestinal stromal tumors: a single center experience retrospective analysis
    Tanimine, Naoki
    Tanabe, Kazuaki
    Suzuki, Takahisa
    Tokumoto, Noriaki
    Ohdan, Hideki
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2012, 10
  • [44] Retrospective study of the clinicopathological characteristics and prognostic factors of gastrointestinal stromal tumors in Chinese patients
    Hu, Xiangchen
    Zhang, Qiqi
    Wang, Zhe
    Ren, Haiyue
    Su, Peng
    Kou, Youwei
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2022, 61
  • [45] Circulating tumor cells as a prognostic and predictive marker in gastrointestinal stromal tumors: a prospective study
    Li, Qiang
    Zhi, Xiaofei
    Zhou, Jianping
    Tao, Ran
    Zhang, Jiaxuan
    Chen, Peisheng
    Roe, Oluf Dimitri
    Sun, Luning
    Ma, Lilin
    ONCOTARGET, 2016, 7 (24) : 36645 - 36654
  • [46] Gastrointestinal stromal tumors
    O'Sullivan, Maureen J.
    PEDIATRIC SURGERY INTERNATIONAL, 2009, 25 (10) : 841 - 850
  • [47] Gastrointestinal Stromal Tumors: Current Management
    Pisters, Peter W. T.
    Patel, Shreyaskumar R.
    JOURNAL OF SURGICAL ONCOLOGY, 2010, 102 (05) : 530 - 538
  • [48] Proteogenomics for the Study of Gastrointestinal Stromal Tumors
    Kondo, Tadashi
    PROTEOGENOMICS, 2016, 926 : 139 - 151
  • [49] Perioperative Treatment of Gastrointestinal Stromal Tumors
    Fernandes, Gustavo dos Santos
    Blanke, Charles D.
    Freitas, Daniela
    Guedes, Rodrigo
    Hoff, Paulo M.
    ONCOLOGY-NEW YORK, 2009, 23 (01): : 54 - 61
  • [50] Gastrointestinal stromal tumors
    Beham, Alexander W.
    Schaefer, Inga-Marie
    Schueler, Philipp
    Cameron, Silke
    Ghadimi, B. Michael
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2012, 27 (06) : 689 - 700